Clinical Efficacy of Dapagliflozin in Patients wth Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction Associated with Coronary Artery Disease
Chonghuai Gu, Xuejun Xiang, Yuanxi Zheng, Aijiao Sun, Jing Chen, Rui Qiao, Xin Zhao
Abstract
Objective To study the clinical efficacy of Dapagliflozin in patients with coronary heart disease (CHD) combined with Heart Failure with Reduced Ejection Fraction (HFrEF) and type 2 diabetes mellitus (T2DM). Methods A retrospective analysis of 202 patients with CHD and T2DM who were hospitalized in our department of cardiovascular medicine and/or underwent PCI treatment from November 2019 to November 2022 was conducted. Patients were divided into two groups according to whether they received Dapagliflozin treatment: the Dapagliflozin group (n=100) and the control group (n=102). A subgroup analysis was performed on the 80 HFrEF patients in the total population, which was also divided into two groups: the Dapagliflozin group (n=44) and the control group (n=36). The incidence of major adverse cardiovascular events (MACE) during hospitalization and the median follow-up period (224.5 days) was recorded and analyzed in both the total population and the subgroup. ResultsThe results of the analysis of the total patient population showed no statistical differences between the two groups in baseline data and related clinical treatment conditions (P>0.05). The follow-up period events analysis showed that the overall MACE event rate in the Dapagliflozin group was lower than that in the control group (6.00% vs. 17.65%), but not statistically significant (P=0.071). The COX regression analysis of MACE events showed that the use of Dapagliflozin was an independent protective factor for MACE events [HR=0.166, 95% CI (0.026-0.953), P=0.047]. In the HFrEF subgroup analysis, there was no significant difference between the two groups in the baseline data analysis (P>0.05). The COX regression analysis in the subgroup analysis showed that the use of Dapagliflozin was a strong protective factor for the HFrEF subgroup during the follow-up period [HR=0.250, 95% CI (0.017-0.518), P<0.001]. Further analysis using the Kaplan-Meier method showed that the event rate in the Dapagliflozin group was significantly lower than that in the control group. Conclusion The use of Dapagliflozin in patients with CHD combined with HFrEF and T2DM may be effective in reducing the incidence of MACE.
Full Text: PDF DOI: 10.15640/ijhs.v11n2a16
Today
All Days
Online